|
|
Volumn 18, Issue SUPPL. 9, 2007, Pages
|
|
New challenges in kidney cancer therapy: Bevacizumab
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
BEVACIZUMAB;
INTERLEUKIN 2;
PLACEBO;
SUNITINIB;
MONOCLONAL ANTIBODY;
RECOMBINANT PROTEIN;
CANCER INHIBITION;
CANCER SURVIVAL;
CLEAR CELL CARCINOMA;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
CONFERENCE PAPER;
DISEASE COURSE;
DISEASE FREE SURVIVAL;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG MECHANISM;
DRUG MEGADOSE;
DRUG PROTEIN BINDING;
DRUG RESPONSE;
DRUG WITHDRAWAL;
HUMAN;
HYPERTENSION;
KIDNEY CANCER;
MONOTHERAPY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROTEINURIA;
TREND STUDY;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
GENETICS;
KIDNEY CARCINOMA;
KIDNEY TUMOR;
METABOLISM;
PATHOLOGY;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
CARCINOMA, RENAL CELL;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE III;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
HUMANS;
HYPERTENSION;
KIDNEY NEOPLASMS;
PROTEINURIA;
RANDOMIZED CONTROLLED TRIALS;
RECOMBINANT PROTEINS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 36049050063
PISSN: 09237534
EISSN: 15698041
Source Type: Journal
DOI: 10.1093/annonc/mdm300 Document Type: Conference Paper |
|
Times cited : (5)
|
|
References (1)
|
